What You Should Know
- The Deal: Swedish medical imaging and cybersecurity giant Sectra has entered into an agreement to acquire Oxipit, a Lithuanian startup specializing in AI-based radiology solutions. The deal is expected to close in March 2026.
- The Tech Shift: While most radiology AI currently acts as a “co-pilot” (flagging findings and acting as decision support), Oxipit pioneers autonomous AI. Its technology is validated to independently complete specific diagnostic tasks without human intervention.
- The Flagship Product: Oxipit’s ChestLink holds the world’s first CE Class IIb certification for autonomous AI in chest X-ray analysis. It automatically identifies and clears high-confidence “normal” chest X-rays from the radiologist’s worklist.
- The Strategic Integration: The Oxipit team will transition into a dedicated AI development center within Sectra’s Imaging IT Solutions division. Meanwhile, Sectra’s Amplifier service will remain an open, vendor-neutral ecosystem for third-party AI applications.
From Co-Pilot to Autopilot
Imaging volumes are rising globally, while the workforce of trained radiologists is shrinking, leading to massive reporting backlogs. A significant percentage of daily imaging volume—particularly routine chest X-rays—consists of perfectly healthy, “normal” scans. Forcing a highly specialized, highly compensated radiologist to spend hours manually dictating “no acute cardiopulmonary disease” is a massive misallocation of clinical resources.
Oxipit’s flagship product, ChestLink, solves this exact bottleneck. Operating under rigorous, validated safety thresholds, ChestLink automatically identifies high-confidence normal chest X-rays and actually clears them from the worklist, finalizing the report without any human intervention. Through the automation of healthy cases, the human radiologist’s queue is instantly enriched with scans that actually require their clinical expertise and judgment.
The Regulatory Moat
In healthcare AI, the algorithm is only half the battle; the other half is regulatory clearance. Autonomous AI represents an entirely different risk profile than standard Computer-Aided Detection (CAD).
ChestLink holds a CE Class IIb certification, which reflects the elevated regulatory and clinical validation standards required to allow a machine to practice medicine independently within the European Economic Area (EEA). By acquiring Oxipit, Sectra isn’t just buying an algorithm; it is buying a highly defensible regulatory moat and a team that has already proven it can navigate the strictest clinical safety standards.
